In BioCentury, David McIntosh Discusses Implications of Biosecure Act on Biopharmaceutical Companies

In a BioCentury article, life sciences licensing partner David McIntosh discussed potential implications of the Biosecure Act to address concerns that Chinese biotechnology companies pose national security threats.

David notes the U.S. Senate bill was amended to grandfather existing contracts, but it is not yet clear how the grandfathering process will apply.

“Grandfathering may not address all the supply constraint issues created by the bill. For instance, if the law were to exempt drugs that are being manufactured by a Chinese ‘biotechnology company of concern’ for commercial supply at the time of enactment, but did not exempt drugs being manufactured by that same Chinese company for clinical development at the time of enactment (meaning that manufacture of those drugs would need to be transferred to another company for commercial supply), then that would still have a pretty dramatic financial impact on the affected U.S. biotech companies who are forced to switch manufacturers and could also delay the and launch of a fair number of drugs that are currently in development,” said David.